Journal
JOURNAL OF CONTROLLED RELEASE
Volume 320, Issue -, Pages 363-380Publisher
ELSEVIER
DOI: 10.1016/j.jconrel.2020.01.047
Keywords
Ulcerative colitis; Macrophage; Drug delivery system; Inflammation; Nanomedicine
Funding
- Program of Shanghai Committee of Science and Technology, China [17401902300]
- NFSC [81925035, 81673382, 81521005]
- Strategic Priority Research Program of CAS [XDA12050307]
- National Special Project for Significant New Drugs Development [2018ZX09711002-010-002]
- CAS Scientific Research and Equipment Development Project [YZ201437]
- Fudan-SIMM Joint Research Fund [FU-SIMM20174009]
Ask authors/readers for more resources
Macrophages, an important component of the innate immune response, are a key regulator of intestinal microenvironment homeostasis. These cells essentially contribute to chronic inflammatory diseases due to their strong plasticity. As is known, ulcerative colitis (UC), a chronic inflammatory disease, is closely related to immune dysfunction. A growing body of evidence suggests that the macrophage is a promising drug target for modulating the intestinal immune systems and regulating the inflammatory microenvironment, thus alleviating the inflammatory responses in UC. The macrophage-based therapy strategies for UC are still at an emerging stage. The advanced drug delivery systems can improve the macrophage-based therapy. This article will review the molecular mechanisms related to macrophage polarization and the interactions between signaling pathways that regulate the pathogenesis of UC and summarize the macrophage-based nanotherapeutic strategies in UC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available